Insights & Analysis
Practical guidance on PBM audits, federal investigations, compounding defense, DEA enforcement, telehealth compliance, and the regulatory pressures facing pharmacies and providers nationwide.
More articles — Page 71
Page 71 of 115 · 1039 articles
Managed Care SIU Investigations: What Providers Face
Managed care SIUs are plan-run fraud units, not government auditors, and can trigger prepayment holds, denials, and network termin…
SmithRx Audit Defense for Independent Pharmacies
SmithRx markets transparent pricing, but its network agreement still sets audit, documentation, and recoupment terms independent p…
Refill Too Soon Audit Findings and How to Rebut Them
Why PBMs flag early refills, the legitimate clinical reasons that justify them, and the documentation that survives an audit.
Medicaid Credentialing and Re-Credentialing Denials
How Medicaid provider screening, risk-tier site visits, and exclusion database checks lead to credentialing denials, and how to ap…
Clinical Laboratory Medicare Audits
Medical necessity documentation, standing orders, and kickback exposure that shape how a clinical laboratory Medicare audit unfold…
Preparing for a Board of Pharmacy Compounding Inspection
Mock inspections, staged compliance files, and corrected findings shape how a Board of Pharmacy compounding inspection goes before…
State Controlled Substance Registration Running Parallel to DEA
Most states require their own controlled substance registration alongside the federal DEA number, creating dual jeopardy exposure…
Chronic Care Management Billing Under Audit
CCM claims fail audits over vague time logs, missing consent, and generic care plans. What CMS requires, and what a review looks f…
Pharmacy or Outsourcing Facility: Choosing Your Structure
Comparing 503A pharmacy compounding and 503B outsourcing facility status on prescription rules, cGMP burden, and interstate reach.